WJA
LCTX icon

Williams Jones & Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Williams Jones & Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$112K Sell
101,661
-450
-0.4% -$519 ﹤0.01% 381
2019
Q1 		$134K Buy
102,111
+21,371
+26% +$26.6K ﹤0.01% 389
2018
Q4 		$74K Sell
80,740
-11,546
-13% -$17.7K ﹤0.01% 377
2018
Q3 		$190K Hold
92,286
– – ﹤0.01% 415
2018
Q2 		$166K Hold
92,286
– – ﹤0.01% 416
2018
Q1 		$217K Hold
92,286
– – 0.01% 401
2017
Q4 		$174K Hold
92,286
– – ﹤0.01% 413
2017
Q3 		$229K Hold
92,286
– – 0.01% 387
2017
Q2 		$254K Buy
92,286
+11,762
+15% +$32.9K 0.01% 355
2017
Q1 		$243K Buy
80,524
+11,430
+17% +$32.5K 0.01% 360
2016
Q4 		$218K Hold
69,094
– – 0.01% 349
2016
Q3 		$236K Hold
69,094
– – 0.01% 346
2016
Q2 		$158K Hold
69,094
– – ﹤0.01% 363
2016
Q1 		$173K Buy
69,094
+391
+0.6% +$873 0.01% 309
2015
Q4 		$227K Hold
68,703
– – 0.01% 304
2015
Q3 		$166K Hold
68,703
– – 0.01% 335
2015
Q2 		$201K Buy
68,703
+557
+0.8% +$2.16K 0.01% 352
2015
Q1 		$273K Hold
68,146
– – 0.01% 320
2014
Q4 		$205K Buy
68,146
+6,195
+10% +$16.8K 0.01% 350
2014
Q3 		$157K Hold
61,951
– – 0.01% 317
2014
Q2 		$153K Hold
61,951
– – 0.01% 328
2014
Q1 		$164K Buy
61,951
+30,976
+100% +$91.2K ﹤0.01% 346
2013
Q4 		$90K Hold
30,975
– – ﹤0.01% 326
2013
Q3 		$95K Buy
30,975
+6,195
+25% +$19.6K ﹤0.01% 327
2013
Q2 		$79K Buy
+24,780
New +$79.4K ﹤0.01% 330

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Williams Jones & Associates's LCTX Position: Q2 2019 in Review

Williams Jones & Associates reduced its Lineage Cell Therapeutics (LCTX) stake by 0.44% in Q2 2019, selling an estimated $519 and leaving 101,661 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #381.

Williams Jones & Associates first reported a position in LCTX in Q2 2013 and has held it in 25 quarters since. The position peaked at $273K in Q1 2015. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2019.

  • Williams Jones & Associates held 101,661 shares of Lineage Cell Therapeutics worth $112K as of Q2 2019.
  • Williams Jones & Associates sold 450 Lineage Cell Therapeutics shares in Q2 2019, an estimated $519.
  • Lineage Cell Therapeutics made up ﹤0.01% of Williams Jones & Associates's portfolio in Q2 2019, its #381 holding.
  • Williams Jones & Associates first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 25 quarters since.
  • Williams Jones & Associates's Lineage Cell Therapeutics position peaked at $273K in Q1 2015.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2019.

Based on Williams Jones & Associates's 13F filing for Q2 2019, filed 14 Aug 2019.